Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts

B. Vincze, István Pályi, Dóra Daubner, T. Kremmer, Irene Számel, I. Bodrogi, János Sugár, J. Seprődi, Imre Mezo, István Teplán, Sándor Eckhardt

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The specific binding of luteinizing hormone-releasing hormone (LH-RH) agonist in estradiol-dependent MCF-7 and estradiol-independent MDA-MB-231 human breast cancer cells has been studied using [3H]Ovurelin [d-3H-Phe6),des-Gly10-LH-RH-ethylamide]. The results of Scatchard analyses suggest the presence of a single class of receptor sites, both in cell suspensions and membrane fractions. Evaluation of these peptide receptors appears to reflect additional characteristics of biological behaviour of these human breast cancer cells. The synthetic LH-RH agonist Ovurelin [(d-Phe6),des-Gly10-LH-RH-ethylamide] can directly interfere (25-30%) with the proliferation of MDA-MB-231 human breast cancer cells in culture. The inhibitory effect of Ovurelin in vitro was negligible in the MCF-7 cell line. In the in vivo experiments the treated immunosuppressed mice bearing either MCF-7 or MDA-MB-231 xenografts responded to the high-dose LH-RH analogue Zoladex depot and Decapeptyl depot therapy. Since the MDA-MB-231 tumour was found to be ER-negative it seems possible that the regression of this xenograft results from the direct antitumour action of the LH-RH agonist.

Original languageEnglish
Pages (from-to)119-126
Number of pages8
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume38
Issue number2
DOIs
Publication statusPublished - 1991

Fingerprint

Heterografts
Gonadotropin-Releasing Hormone
Cells
Breast Neoplasms
Cell Line
Estradiol
Bearings (structural)
Triptorelin Pamoate
Goserelin
Peptide Receptors
MCF-7 Cells
Cell culture
Tumors
Suspensions
Cell Culture Techniques
Cell Membrane
Membranes
ovurelin
Neoplasms
Experiments

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. / Vincze, B.; Pályi, István; Daubner, Dóra; Kremmer, T.; Számel, Irene; Bodrogi, I.; Sugár, János; Seprődi, J.; Mezo, Imre; Teplán, István; Eckhardt, Sándor.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 38, No. 2, 1991, p. 119-126.

Research output: Contribution to journalArticle

Vincze, B. ; Pályi, István ; Daubner, Dóra ; Kremmer, T. ; Számel, Irene ; Bodrogi, I. ; Sugár, János ; Seprődi, J. ; Mezo, Imre ; Teplán, István ; Eckhardt, Sándor. / Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. In: Journal of Steroid Biochemistry and Molecular Biology. 1991 ; Vol. 38, No. 2. pp. 119-126.
@article{c0c05d0f943d4a908262672930a24b82,
title = "Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts",
abstract = "The specific binding of luteinizing hormone-releasing hormone (LH-RH) agonist in estradiol-dependent MCF-7 and estradiol-independent MDA-MB-231 human breast cancer cells has been studied using [3H]Ovurelin [d-3H-Phe6),des-Gly10-LH-RH-ethylamide]. The results of Scatchard analyses suggest the presence of a single class of receptor sites, both in cell suspensions and membrane fractions. Evaluation of these peptide receptors appears to reflect additional characteristics of biological behaviour of these human breast cancer cells. The synthetic LH-RH agonist Ovurelin [(d-Phe6),des-Gly10-LH-RH-ethylamide] can directly interfere (25-30{\%}) with the proliferation of MDA-MB-231 human breast cancer cells in culture. The inhibitory effect of Ovurelin in vitro was negligible in the MCF-7 cell line. In the in vivo experiments the treated immunosuppressed mice bearing either MCF-7 or MDA-MB-231 xenografts responded to the high-dose LH-RH analogue Zoladex depot and Decapeptyl depot therapy. Since the MDA-MB-231 tumour was found to be ER-negative it seems possible that the regression of this xenograft results from the direct antitumour action of the LH-RH agonist.",
author = "B. Vincze and Istv{\'a}n P{\'a}lyi and D{\'o}ra Daubner and T. Kremmer and Irene Sz{\'a}mel and I. Bodrogi and J{\'a}nos Sug{\'a}r and J. Seprődi and Imre Mezo and Istv{\'a}n Tepl{\'a}n and S{\'a}ndor Eckhardt",
year = "1991",
doi = "10.1016/0960-0760(91)90116-M",
language = "English",
volume = "38",
pages = "119--126",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts

AU - Vincze, B.

AU - Pályi, István

AU - Daubner, Dóra

AU - Kremmer, T.

AU - Számel, Irene

AU - Bodrogi, I.

AU - Sugár, János

AU - Seprődi, J.

AU - Mezo, Imre

AU - Teplán, István

AU - Eckhardt, Sándor

PY - 1991

Y1 - 1991

N2 - The specific binding of luteinizing hormone-releasing hormone (LH-RH) agonist in estradiol-dependent MCF-7 and estradiol-independent MDA-MB-231 human breast cancer cells has been studied using [3H]Ovurelin [d-3H-Phe6),des-Gly10-LH-RH-ethylamide]. The results of Scatchard analyses suggest the presence of a single class of receptor sites, both in cell suspensions and membrane fractions. Evaluation of these peptide receptors appears to reflect additional characteristics of biological behaviour of these human breast cancer cells. The synthetic LH-RH agonist Ovurelin [(d-Phe6),des-Gly10-LH-RH-ethylamide] can directly interfere (25-30%) with the proliferation of MDA-MB-231 human breast cancer cells in culture. The inhibitory effect of Ovurelin in vitro was negligible in the MCF-7 cell line. In the in vivo experiments the treated immunosuppressed mice bearing either MCF-7 or MDA-MB-231 xenografts responded to the high-dose LH-RH analogue Zoladex depot and Decapeptyl depot therapy. Since the MDA-MB-231 tumour was found to be ER-negative it seems possible that the regression of this xenograft results from the direct antitumour action of the LH-RH agonist.

AB - The specific binding of luteinizing hormone-releasing hormone (LH-RH) agonist in estradiol-dependent MCF-7 and estradiol-independent MDA-MB-231 human breast cancer cells has been studied using [3H]Ovurelin [d-3H-Phe6),des-Gly10-LH-RH-ethylamide]. The results of Scatchard analyses suggest the presence of a single class of receptor sites, both in cell suspensions and membrane fractions. Evaluation of these peptide receptors appears to reflect additional characteristics of biological behaviour of these human breast cancer cells. The synthetic LH-RH agonist Ovurelin [(d-Phe6),des-Gly10-LH-RH-ethylamide] can directly interfere (25-30%) with the proliferation of MDA-MB-231 human breast cancer cells in culture. The inhibitory effect of Ovurelin in vitro was negligible in the MCF-7 cell line. In the in vivo experiments the treated immunosuppressed mice bearing either MCF-7 or MDA-MB-231 xenografts responded to the high-dose LH-RH analogue Zoladex depot and Decapeptyl depot therapy. Since the MDA-MB-231 tumour was found to be ER-negative it seems possible that the regression of this xenograft results from the direct antitumour action of the LH-RH agonist.

UR - http://www.scopus.com/inward/record.url?scp=0026081289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026081289&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(91)90116-M

DO - 10.1016/0960-0760(91)90116-M

M3 - Article

VL - 38

SP - 119

EP - 126

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 2

ER -